Anticorps Monoclonal anti-ITM2C

ITM2C Monoclonal Antibody for IF/ICC, Indirect ELISA

Hôte / Isotype

Mouse / IgG2a

Réactivité testée

Humain

Applications

IF/ICC, Indirect ELISA

Conjugaison

Non conjugué

CloneNo.

2E8G11

N° de cat : 60095-1-PBS

Synonymes

BRICD2C, Cerebral protein 14, E25, E25C, integral membrane protein 2C, ITM2C, ITM3, PSEC0047, Transmembrane protein BRI3



Informations sur le produit

60095-1-PBS cible ITM2C dans les applications de IF/ICC, Indirect ELISA et montre une réactivité avec des échantillons Humain

Réactivité Humain
Hôte / Isotype Mouse / IgG2a
Clonalité Monoclonal
Type Anticorps
Immunogène ITM2C Protéine recombinante Ag4409
Nom complet integral membrane protein 2C
Masse moléculaire calculée230aa,26 kDa; 267aa,30 kDa
Poids moléculaire observé 35 kDa
Numéro d’acquisition GenBankBC025742
Symbole du gène ITM2C
Identification du gène (NCBI) 81618
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

The Integral membrane protein 2C (ITM2C) is a type II integral transmembrane protein belonging to a family composed of at least two other members, ITM2A and ITM2B. ITM2C, often called transmembrane protein BRI3, is highly expressed in brain tissue. Yeast two-hybrid screen system revealed that BRI3 could interact with beta-secretase beta-amyloid protein converting enzyme (BACE)1 and the microtubule-destabilizing protein SCG10 (STMN2). It may play a role in TNF-induced cell death and neuronal differentiation. BRI3 was found to inhibit the various processing of amyloid precursor protein (APP) by blocking the access of alpha- and beta-secretases to APP, competitive inhibition of APP processing by BRI3 may provide a new approach to Alzheimer disease (AD) therapy and prevention.

{{ptg:RelatedPrimaryAntibodies}}